Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628627 | 0.82 | POLB (0.67) | KDM4EPOLBATMALDH1A1RECQL | |
| SCHEMBL848499 | 0.80 | POLB (0.64) | KDM4EPOLBATMALDH1A1RECQL | |
| N-Methylanthranilic Acid SCHEMBL29381752 | 0.80 | KDM4E (0.64) | KDM4EPOLBATMALDH1A1FABP3 | |
| SCHEMBL6964053 | 0.80 | KDM4E (0.64) | KDM4EPOLBATMALDH1A1RECQL | |
| N-Methylanthranilic Acid SCHEMBL130356 | 0.80 | KDM4E (0.64) | KDM4EPOLBATMALDH1A1FABP3 | |
| SCHEMBL31087257 | 0.80 | POLB (0.64) | KDM4EPOLBATMALDH1A1RECQL | |
| SCHEMBL10435012 | 0.79 | CYP2C19 (0.65) | KDM4EPOLBALDH1A1SMN1; SMN2HPGD | |
| N-Methylanthranilic Acid SCHEMBL9787433 | 0.78 | KDM4E (0.62) | KDM4EPOLBATMALDH1A1FABP3 | |
| SCHEMBL2061071 | 0.78 | POLB (0.62) | KDM4EPOLBATMALDH1A1RECQL | |
| N-Methylanthranilic Acid SCHEMBL8552208 | 0.78 | KDM4E (0.62) | KDM4EPOLBATMALDH1A1FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189708-A1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | HIROSAKI UNIVERSITY (JP) | 2011-08-04 | — | — | US | claimed |
| EP-2325327-A1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | Hirosaki University (JP) | 2011-05-25 | — | — | EP | claimed |
| US-9958450-B2 | L-glucose derivatives having fluorescent chromophore | HIROSAKI UNIVERSITY (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20150212094-A1 | L-glucose derivatives having fluorescent chromophore | ORBIO CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-8986656-B2 | Method for evaluating specific incorporation of D-glucose into cells | HIROSAKI UNIVERSITY (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2325327-B1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | UNIV HIROSAKI (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20110189708-A1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | HIROSAKI UNIVERSITY (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2325327-A1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | Hirosaki University (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| US-5684029-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | disclosed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| US-5385925-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0468470-A1 | Benzimidazoles, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189708-A1 | METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS | SLC2A4, SLC2A3, SLC2A1 | KDM4E 3554/4885POLB 4071/4885ATM 3731/4885 |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | KDM4E 962/4885POLB 1262/4885ATM 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.